Written questions by McVey.

What is the projected cost of the Peak Cluster project.

Awaiting answer.

How much cement will be used to build the Peak Cluster project, including the pipeline, onshore storage facility, pipeline to the sea, in-sea storage facility and any other associated construction work.

Awaiting answer.

If he will publish the cost-benefit analysis of the Peak Cluster project.

Awaiting answer.

What assessment he has made of the potential environmental impact of the Peak Cluster project in a) cost, b) foliage, and c) endangered species.

Awaiting answer.

What consideration he has given to the importing of CO2 from international sources for the Peak Cluster project.

Awaiting answer.

That based on the latest consultation from the DHSC on the Nutrient Profile Model (NPM), and given that most fruit yogurts are low in fat and much lower in calories than many alternative desserts and snacks, what evidence is the Government using to substantiate its policy that yogurt is a major contributor to childhood obesity.

Awaiting answer.

With reference to FOI 903 to the UK Health Security Agency (UKHSA), what assessment he has made of the implications for trust and confidence in the pharmaceutical industry’s self-regulatory system, and in the Moderna-UK Strategic Partnership, if audit documents such as this one are not shared with government agencies for scrutiny.

Awaiting answer.

With reference to FOI 903 to the UK Health Security Agency (UKHSA), whether a copy of the Moderna audit has been requested from the Prescription Medicines Code of Practice Authority (PMCPA).

Awaiting answer.

With reference to FOI 903 to the UK Health Security Agency (UKHSA), whether the Medicines and Healthcare products Regulatory Agency has a copy of the Prescription Medicines Code of Practice Authority's audit of Moderna.

Awaiting answer.

With reference to his Department's Pandemic Preparedness Strategy: building our capabilities, published on 25 March 2026, how the word pandemic is defined.

It has not proved possible to respond to the hon. Member in the time available before Prorogation.

With reference to his Department's Pandemic Preparedness Strategy: building our capabilities, published on 25 March 2026, what type of pathogens the strategy is concerned with.

Awaiting answer.

If he will publish the cost-benefit analysis relating to the Peak Cluster project.

Awaiting answer.

With reference to his Department's Pandemic Preparedness Strategy: building our capabilities, published on 25 March 2026, for what reason the strategy does not include modelling.

It has not proved possible to respond to the hon. Member in the time available before Prorogation.

Whether he considered including hospital-acquired infections in his Department's Pandemic Preparedness Strategy: building our capabilities, published on 25 March 2026.

Awaiting answer.

When the Pandemic Preparedness Strategy: building our capabilities, published on 25 March 2026, was written.

It has not proved possible to respond to the hon. Member in the time available before Prorogation.

With reference to his Department's Pandemic Preparedness Strategy: building our capabilities, published on 25 March 2026, (a) who wrote the document and (b) whether AI technology was involved.

It has not proved possible to respond to the hon. Member in the time available before Prorogation.

For what reason the new biosecurity centre in Harlow will not be operational until 2038.

Awaiting answer.

Whether his Department has undertaken analysis of the number of jobs that will be created by the Peak Cluster project.

It has not proved possible to respond to the Rt hon. Member in the time available before Prorogation.

What assessment he has made of the potential implications for his Department's policies of the increasing percentage of funding for the World Health Organization coming from (a) specified and (b) non-State donor funding.

The Department remains committed to ensuring investments in World Health Organization (WHO) and other multilateral health initiatives deliver strong value for money. Flexible funding supports WHO to direct resources to greatest need and Member States-agreed priorities, improving efficiency and independence whereas specified, or earmarked, funding constrains effectiveness and fragments delivery. The United Kingdom remains one of WHO’s most significant donors and the top provider of flexible funding.WHO gets the largest proportion of its funding from Member States. WHO’s reporting shows that the share of flexible funding has increased in recent years. The Department’s contribution to WHO consists of the annual mandatory membership fee, which is fully flexible and based on gross national income. WHO funding is available to view publicly on their programme budget portal, with further information available at the following two links:https://www.who.int/about/accountability/budget/programme-budget-digital-platform-2026-2027https://open.who.int/2024-25/homeWHO priorities are agreed by all Member States, including the UK through the negotiation of a general programme of work and programme budgets. Then donors, including Member States and others, fund those agreed priorities. WHO’s General Programme of Work 2025 to 2028 was agreed by Member States at the World Health Assembly in 2024.WHO engagement with the private sector is guided by WHO’s Framework for Engagement with Non-state Actors which was negotiated and agreed by WHO Member States, including the UK, in 2016. The framework seeks to ensure WHO’s engagement with non-state actors, including the private sector, are managed transparently and supports implementation of the organisation’s policies and recommendations as decided by Member States through the governing bodies. It is publicly available to view on WHO’s website, or at the following link:https://apps.who.int/gb/bd/PDF/Framework_Engagement_non-State_Actors.pdf

Commonwealth and Development Affairs, what assessment she has made of the potential implications for her Department's policies of the increasing percentage of funding for the World Health Organization coming from (a) specified and (b) non-State donor funding.

The UK recognises the importance of flexible and predictable funding for the World Health Organization (WHO). That is why we prioritise fully flexible funding to ensure the organisation's ability to set independent priorities and respond to emerging global health risks. While specified and non State funding remains part of WHO's financing mix, its reporting shows that the share of flexible funding has increased in recent years. The UK continues to advocate for a balanced funding model to strengthen WHO's effectiveness, independence, and accountability. Member States have also agreed reforms to assessed contributions to increase the amount of flexible funding available.